Conciseness

The body is dense with non-obvious operational knowledge (parameter gotchas, broken-tool warnings, response-format quirks) and doesn't re-explain generic concepts. However, sections like the TCF7L2/Wnt worked example and the "Undruggable... does not mean permanently undruggable" paragraph spend tokens on biology exposition Claude could largely supply itself. This matches 'efficient; minor instances of over-explanation that could be trimmed' — not a 5, but well above the 'mostly efficient with some unnecessary explanation' midpoint.

Actionability

Guidance is highly concrete: exact tool names with parameter signatures ("ReactomeAnalysis_pathway_enrichment(identifiers=\"P04637 P38398 ...\")\" — space-separated UniProt STRING, not an array"), exact param gotchas, and some real values (ENSG00000148737.11, species=9606, gtex_v8). What's missing for a 5 is a copy-paste-ready worked example — the calls use placeholders like <disease> and <gene>, and there is no complete end-to-end invocation or Python snippet showing the 'compute, don't describe' mandate in practice. This fits 'mostly executable guidance; concrete code or commands with minor gaps'.

Workflow Clarity

The Three-Step Workflow (GWAS to causal gene → enrichment → drug target) is clearly sequenced with numbered steps, evidence tiers (High/Medium/Low), and cross-validation checkpoints (cross-check with OpenTargets, converge across Reactome/KEGG/STRING). This matches 'clear sequence with most checkpoints present; minor validation gaps' — the rankings are conceptual formulas ("enrichment FDR x number of GWAS genes x biological plausibility") rather than defined procedures, and there is no explicit verify-output step. Not a 3 because decision checkpoints (evidence tiers, convergence criteria, classification of candidates) are present and explicit.

Progressive Disclosure

No bundle files exist (no references/, scripts/, or assets/), so the skill is a single self-contained document — no nested or dead references. Sections are well-organized with clear headers (When to Use, Tool Selection Guide by phase, Three-Step Workflow, Gotchas, Limitations, Related Skills). This fits 'good structure; most content is appropriately placed; minor organization gaps' — not a 5 because at ~157 lines the Tool Selection Guide and Key Parameter Gotchas sections are candidates for a separate reference file if the skill grows, keeping the core even leaner.

Specificity

The description lists multiple concrete actions in a clear pipeline: "Maps GWAS hits to causal genes (via fine-mapping/eQTL), then to pathways (Reactome, KEGG, WikiPathways), then to existing drugs hitting those pathways." This matches the anchor 'lists multiple specific concrete actions; comprehensive coverage' — it names each pipeline stage, the data sources, and the analytical method. Not a 4 because there are no meaningful coverage gaps; every phase of the workflow (gene mapping, pathway mapping, drug lookup) is explicitly named.

Completeness

It explicitly answers 'what' ("Connect GWAS variants to biological pathways and druggable targets. Maps GWAS hits to causal genes... then to pathways... then to existing drugs") and 'when' ("Use for pathway-level disease mechanisms, druggable-pathway prioritization from GWAS, SNP-to-pathway-to-target tracing, and tissue-specific eQTL evidence for drug target hypotheses"). This matches the anchor 'clearly and explicitly answers both what AND when with concrete trigger phrases'. Not a 4 because the 'when' clause is not merely present but enumerates four concrete trigger scenarios.

Trigger Term Quality

Trigger terms are comprehensive and natural for this domain: "pathway-level disease mechanisms", "druggable-pathway prioritization from GWAS", "SNP-to-pathway-to-target tracing", "tissue-specific eQTL evidence" — plus synonyms like GWAS variants, SNP/variant, drug targets, causal genes. A user asking any of these questions would naturally use these phrases. Not a 4 because both the technical terms and their common variations (GWAS/SNP/variant; drug target/druggable) are covered.

Distinctiveness Conflict Risk

The description carves out a clear niche — pathway-level GWAS-to-drug-target tracing — with distinct triggers (pathway mechanisms, druggable-pathway prioritization, SNP-to-pathway tracing) unlikely to fire for generic genetics or drug-lookup skills. It uses third person throughout ('Connect', 'Maps'). Not a 4 because even against closely related sibling skills (GWAS-to-gene, enrichment-only), the pathway-to-drug-target framing is uniquely specific to this skill.